Swiss National Bank’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Swiss National Bank’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-21,800	Closed	-$2.87M	–	2492
2020 Q4	$2.87M	Buy	21,800 +300	+1%	+$26.5K	﹤0.01%	1698
2020 Q3	$1.09M	Hold	21,500	–	–	﹤0.01%	2050
2020 Q2	$1.02M	Buy	21,500 +7,000	+48%	+$326K	﹤0.01%	2085
2020 Q1	$710K	Buy	14,500 +400	+3%	+$20.4K	﹤0.01%	2007
2019 Q4	$809K	Buy	14,100 +400	+3%	+$19.8K	﹤0.01%	2251
2019 Q3	$493K	Hold	13,700	–	–	﹤0.01%	2365
2019 Q2	$426K	Buy	+13,700	New	+$371K	﹤0.01%	2458

Swiss National Bank's EIDX Position: Q1 2021 in Review

Swiss National Bank sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 21,800 shares — an estimated $2.87M sold.

Swiss National Bank first reported a position in EIDX in Q2 2019 and held it in 7 quarters. The position peaked at $2.87M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Swiss National Bank reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Swiss National Bank sold 21,800 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.87M.
Swiss National Bank first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 7 quarters.
Swiss National Bank's Eidos Therapeutics, Inc. Common Stock position peaked at $2.87M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Swiss National Bank's 13F filing for Q1 2021, filed 7 May 2021.